Abstract
SUMMARY In the management of clotting in Scribner shunts, urokinase was of value in removing clot and thereby extending shunt life. During a trial involving 16 shunts over 40.5 patient months, no significant benefit was detected from the introduction of urokinase into the venous side of the shunt prior to each dialysis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
